mRNA Drug Kostive Faces Scrutiny Ahead of Potential Release
BUCHAREST – may 18, 2024 – Concerns are mounting over the impending release of the mRNA drug Kostive. The self-deploying mRNA treatment, already approved in Europe, is facing scrutiny from experts like Dr. Giovanni Frajese who express worries about its long-term effects and potential risks, including the transmission of genetic code to other organisms.This situation raises critical questions about the future of healthcare. Read on for potential repercussions.
mRNA Drug Kostive faces Scrutiny Ahead of Potential Release
A new chapter in mRNA-based drug distribution could begin as early as June 9 with the potential release of Kostive, a self-deploying mRNA drug. This has sparked debate among experts and observers, especially regarding the safety and long-term effects of this innovative therapy.
Concerns Raised Over Safety and Long-Term Effects
Dr.Giovanni Frajese, an endocrinologist, has voiced concerns about the potential risks associated with this new drug. He emphasized the need for more in-depth research, stating:
We tried to make some data on this issue as, behind the use of recombinant RNAs, there is a concrete risk.
Dr. Frajese highlighted the potential for the genetic code to be transmitted outside the body and self-replicated through microvesicles, exosomes, and similar structures, referencing insights from Professor Federico of the Istituto Superiore di Sanità.
According to Dr. Frajese, this transmission could extend beyond humans to:
Any living creature, plant or animal that it is.
He believes this possibility has not been adequately studied before the drug’s potential release.
The Rush to mRNA and the Limits of Current Studies
Concerns also exist regarding the depth of study into the medium and long-term effects of mRNA therapies. dr. Frajese expressed concern over the current focus on RNA technology, stating:
Today’s medicine seems to want to focus everything on this squeak in RNA, as if it were the panacea of all evils. Unfortunately, we really proceed blindly, without minimally studying the consequences on the human body.
He suggests that the approval process for new drugs still reflects the urgency of the COVID-19 pandemic, even though that period has passed.
Pharmaceutical companies continue to move as if the Covid emergency was still in progress,but so it is not.
European Approval and Potential Risks
While the approval process in the United States remains in its early stages, the European medicines Agency (EMA) has already approved Kostive.Dr.Frajese warned:
if nobody opposes, on June 9 we will find ourselves with a deadly unknown one on the market. It will take years to understand the real effects of this drug.
He also emphasized the potential marginalization of traditional and less invasive health approaches, such as:
Natural medicine, correct physical education, balanced diet and vitamin integration.
Dr. Frajese believes these methods are often overlooked in favor of mRNA technology, which he suggests is:
More interesting and above all more profitable.
Ignoring Existing Scientific Literature
Dr. Frajese expressed skepticism about the effectiveness and safety of mRNA drugs,noting:
There is a wide scientific literature that raises crucial doubts about safety. Yet, those who govern the agencies of the European drug choose to ignore these evidence, effectively transforming the population and the habitat into unaware guinea pigs.
He called for a:
Radical change in health policy.
Advocating for a courageous and obvious approach based on rigorous scientific studies, he stated:
only so can science recover its true meaning, speaking data in hand and not with dogmas.
Concluding with a sense of urgency, Dr.frajese stated:
This is not the direction we are following, the government has 5 days to oppose.
